How many FDA actions does Argus HQ track for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences?

1 total: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences?

April 29, 2026. Argus HQ ingests new FDA enforcement records daily.

Has Sourav K. Mishra, M.D. / All India Institute of Medical Sciences received FDA warning letters?

Yes, 1 warning letter on file. See the full history below for each one.

Is this FDA enforcement data for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Sourav K. Mishra, M.D. / All India Institute of Medical Sciences's Complete FDA Record

FDA action counts

Total FDA actions	1
Warning letters	1
Recalls	0
Approval records	0
Form 483 inspection citations	0
Most recent action	April 29, 2026

In short: Argus HQ has recorded 1 FDA events for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences: 1 warning letters, 0 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-04-29 to 2026-04-29. The most severe rating Argus HQ has assigned across this history is "medium". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2026-04-29, Argus HQ recorded an FDA Warning Letter for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences, rated "medium" severity in Argus HQ's classification: Sourav K. Mishra, M.D. / All India Institute of Medical Sciences — In Vivo Bioavailability-Bioequivalence Studies – Clinical (2026-04-29). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

How many FDA actions does Argus HQ track for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences?: 1 total: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.
What is the most recent FDA action on file for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences?: April 29, 2026. Argus HQ ingests new FDA enforcement records daily.
Has Sourav K. Mishra, M.D. / All India Institute of Medical Sciences received FDA warning letters?: Yes, 1 warning letter on file. See the full history below for each one.
Is this FDA enforcement data for Sourav K. Mishra, M.D. / All India Institute of Medical Sciences official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Sourav K. Mishra, M.D. / All India Institute of Medical Sciences — In Vivo Bioavailability-Bioequivalence Studies – Clinical (2026-04-29) →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Sourav K. Mishra, M.D. / All India Institute of Medical Sciences's Complete FDA Record. Digital Empire LLC. Retrieved from https://argushq.ai/company/sourav-k-mishra-m-d-all-india-institute-of-medical-sciences

MLA

"Sourav K. Mishra, M.D. / All India Institute of Medical Sciences's Complete FDA Record." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/sourav-k-mishra-m-d-all-india-institute-of-medical-sciences.

Chicago

Argus HQ Research. "Sourav K. Mishra, M.D. / All India Institute of Medical Sciences's Complete FDA Record." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/sourav-k-mishra-m-d-all-india-institute-of-medical-sciences.

BibTeX

@misc{argushq_argushq_ai_company_sourav_k_mishra_m_d_all_india_institute_of_medical_sciences_2026,
  title = {Sourav K. Mishra, M.D. / All India Institute of Medical Sciences's Complete FDA Record},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/sourav-k-mishra-m-d-all-india-institute-of-medical-sciences},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗